MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

PURPOSE: O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added to radiotherapy (RT). It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, l...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: van den Bent, Martin J., Dubbink, Hendrikus J., Sanson, Marc, van der Lee-Haarloo, Cathleen R., Hegi, Monika, Jeuken, Judith W.M., Ibdaih, Ahmed, Brandes, Alba A., Taphoorn, Martin J.B., Frenay, Marc, Lacombe, Denis, Gorlia, Thierry, Dinjens, Winand N.M., Kros, Johan M.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2009
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793037/
https://ncbi.nlm.nih.gov/pubmed/19901104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.1034
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires